Back to All Resources

IRAK4 Degradation vs Inhibition

November 14, 2023

IRAK4 Program Background

Kymera-IRAK4-Degrader-Advantage-Image
View Program Background
Area of Focus
Immunology Targeted Protein Degradation
Programs
IRAK4 (KT-474)
Indications
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link

You may also be interested in these resources

November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
View Resource
August 16, 2023
Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases
American Chemical Society (ACS) Fall 2023 Meeting
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
View Resource
May 18, 2023
Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis
European Academy of Dermatology & Venereology (EADV) Symposium 2023
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
View Resource